[NYC session] Meet with... Canaan Partners

Jun 27 2017https://www.eventbrite.com/e/nyc-session-meet-with-canaan-partners-tickets-33494...

Canaan Partners is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $4.2 billion under management, a diversified fund and 190 exits to date, Canaan has funded some of the world's leading technology companies including LendingClub, Ebates, PrimeSense, and Skybox Imaging as well as healthcare stars like Chimerix, Durata, Labrys Biologics, Novira, CytomX and Civitas Therapeutics. Canaan is currently investing in a $675 million fund focused on early stage IT and healthcare startups. The fund's healthcare focus includes early stage biopharma, medical devices, and digital health.

Colleen Cuffaro will be in attendance on June 27th to provide an overview presentation of Canaan's areas of interest and best practices when applying for funding. Colleen will be on hand to meet with a handful of applicants one-on-one after the presentation.

10:30 AM | Registration Opens and Networking
11:00 AM | Presentation and Q&A
11:45 AM | Networking Lunch
1:00-5:00 PM | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on June 1st.

Canaan Partners Participating Representative:
Colleen Cuffaro | Principal, Canaan Partners
Colleen is a Principal on Canaan's Healthcare Team. She recently led Canaan's investment in Arrakis Therapeutics and sits on their board. Colleen holds an operational role at Antiva Biosciences and observes on the boards of Spyryx Biosciences, NextCure, and Arvinas. Previously she was a board observer at Novira Therapeutics which was acquired by Johnson & Johnson. Prior to joining Canaan in 2014, Colleen worked as a chemist at PMRS, Inc (Pharmaceutical Manufacturing and Research Services, Inc) . Her responsibilities included analytical support of drug product development, ranging from preclinical feasibility studies to commercial supply. She also interned as a bioscience analyst for the inaugural class of Entrepreneurship Lab NYC, an accelerator program for healthcare startups. Colleen holds a Ph.D. in Cellular and Molecular Physiology from Yale University, where her research was aimed at identifying a role for aberrant intracellular calcium signals in the development of metabolic syndrome. She served as co-president of the Yale Healthcare and Life Sciences Club and organized the annual Yale Business of Biotech seminar. Colleen also holds a BA in Chemistry from the University of Pennsylvania. Read more here.
Connect with Colleen: Connect on LinkedIn

Presentation & Lunch
$ 25 | General Public
$ 35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on June 26th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on June 1st. Your application will be reviewed and you will be notified of acceptance by email. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.

About the Meet with... Series:
The purpose of the Meet with series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, OrbiMed, Osage University Partners, Spectrum 28, Quark Venture, and AbbVie Ventures.

New York Genome Center
101 6th Ave
1st Floor
New York, NY 10013